Rocket
Premium
Excel Add-In
International
Tools
Dashboard
Screener
Spinoffs
IPOs
Register
Alerts
Sign In
Overview
Financials
News + Filings
Key Docs
Ownership
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Alvotech
Create:
Alert
All
|
News
|
Filings
Date Filed
Type
Description
10/12/2023
6-K
Quarterly results
10/03/2023
6-K
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
"
FORM 6-K
",
"
Alvotech Enters into Exclusive Licensing Agreement with Kashiv BioSciences for Development and Commercialization of a Proposed Biosimilar to Xolair®
"
08/01/2023
6-K
Quarterly results
07/24/2023
6-K
Quarterly results
07/24/2023
424B3
Form 424B3 - Prospectus [Rule 424(b)(3)]:
07/24/2023
424B3
Form 424B3 - Prospectus [Rule 424(b)(3)]:
07/24/2023
EFFECT
Form EFFECT - Notice of Effectiveness:
07/21/2023
EFFECT
Form EFFECT - Notice of Effectiveness:
07/14/2023
F-3
Form F-3 - Registration statement by foreign private issuers:
07/14/2023
POS AM
Form POS AM - Post-Effective amendments for registration statement:
07/12/2023
6-K
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
"
Master License and Supply Agreement by and between Alvotech and Mercury Pharma Group Limited (trading as Advanz Pharma Holdings)
",
"
Termination Agreement (Vedolizumab) by and between Alvotech and STADA Arzneimittel AG
",
"
Termination Agreement (Golimumab) by and between Alvotech and STADA Arzneimittel AG
",
"
Termination Agreement (Denosumab) by and between Alvotech and STADA Arzneimittel AG
",
"
Master License and Supply Agreement by and between Alvotech and Mercury Pharma Group Limited (trading as Advanz Pharma Holdings)
"
06/29/2023
424B3
Form 424B3 - Prospectus [Rule 424(b)(3)]:
06/29/2023
6-K
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
"
6-K
",
"
Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02 REYKJAVIK, Iceland, June 28, 2023 - Alvotech , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the US Food and Drug Administration has issued a complete response letter for Alvotech's second Biologics License Application for AVT02, a high-concentration biosimilar candidate for Humira ® . As the second of two BLAs submitted for AVT02, this BLA contained data to support approval as a high-concentration biosimilar and additional information to support the interchangeability designation. The CRL noted that certain deficiencies, which were conveyed following the FDA's reinspection of the company's Reykjavik facility t...
"
06/13/2023
6-K
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
"
6-K
",
"
Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara ®
"
06/06/2023
424B3
Form 424B3 - Prospectus [Rule 424(b)(3)]:
06/06/2023
6-K
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
"
6-K
",
"
2023 AGM Minutes
",
"
Announcement of the results of the 2023 AGM
",
"
Amended and restated articles of association of Alvotech
",
"
Announcement Granting of Stock Options
"
05/24/2023
424B3
Form 424B3 - Prospectus [Rule 424(b)(3)]:
05/24/2023
6-K
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
"
6-K
",
"
Alvotech and Advanz Pharma extend strategic partnership to commercialize five proposed biosimilars in Europe
"
05/19/2023
6-K
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
"
6-K
",
"
Alvotech Reports Financial Results for First three Months of 2023 and Provides Business Update
"
05/05/2023
6-K
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
"
Convening notice to the Annual and Extraordinary General Meeting of Shareholders
",
"
Convening notice to the Annual and Extraordinary General Meeting of Shareholders
",
"
Proxy Card
",
"
Proxy Card
",
"
Proxy Card
"
05/04/2023
6-K
Quarterly results
04/14/2023
424B3
Form 424B3 - Prospectus [Rule 424(b)(3)]:
04/14/2023
6-K
Quarterly results
03/28/2023
6-K
Quarterly results
03/17/2023
EFFECT
Form EFFECT - Notice of Effectiveness:
03/13/2023
POS AM
Form POS AM - Post-Effective amendments for registration statement:
03/01/2023
20-F
Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
03/01/2023
6-K
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
"
6-K
",
"
Alvotech Reports Financial Results for Full Year 2022 and Provides Business Update
",
"
Corporate Governance Report
",
"
ESG Report
"
02/14/2023
SC 13G
Oaktree Acquisition Holdings II, L.P. reports a 5.9% stake in Alvotech
02/10/2023
424B3
Form 424B3 - Prospectus [Rule 424(b)(3)]:
02/10/2023
424B3
Form 424B3 - Prospectus [Rule 424(b)(3)]:
02/10/2023
6-K
Quarterly results
02/09/2023
424B3
Form 424B3 - Prospectus [Rule 424(b)(3)]:
02/09/2023
424B3
Form 424B3 - Prospectus [Rule 424(b)(3)]:
Next >>
Rocket Data Systems, Inc. © 2019 |
Contact Us
|
Data Disclaimer
|
Terms of Use
|
Privacy